Adaptive landscapes of antibiotic resistance: population size and 'survival-of-the-flattest'.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

We have recently identified a dramatic drop, at low population sizes, in critical mutation rates. Above these rates a narrow fitness peak may be lost while a broad fitness peak is maintained in a population i.e. 'survival-of-the-flattest'. This brings such thresholds into the range of actual biological mutation rates. This effect could be important in determining evolutionary trajectories, e.g. in the evolution of antibiotic resistance. We therefore propose to test if such effects occur in practice. This requires a multi-disciplinary approach to develop and integrate wet-lab experimental evolution, computer simulation and theory. In the wet-lab we shall evolve Escherichia coli resistant to different antibiotics. Evolution at high population sizes will climb adaptive peaks, at minimal population sizes (mutation accumulation) will move down them and complete genome sequencing will determine the numbers of peaks involved. In simulations we shall develop state-of-the-art GPGPU implementations to relax various biologically unrealistic assumptions in current models. Thus we shall test e.g. the population size dependence in biologically realistic fitness landscapes. At the same time we shall develop existing theory of error thresholds to address critical mutation rates, finite, small populations and more biologically realistic fitness landscapes. We shall test the integration of theory, simulation and biology through close feedback between theory and simulation, experimental evolution at small but not minimal population sizes and detailed tests on specific mutations to identify pleiotropic effects. Together this will test the potential role of the relationship between population size and mutation rate thresholds in biology. This has the potential to link a well-established area of theory and simulation much more closely with biology and to bring timely, critical and novel insights into the crucial area of anti-microbial resistance evolution.

Who will benefit from this research?
Beneficiaries will include:

a) The wider scientific community and those who benefit from their research. This applies particularly to those with interests in antibiotics, healthcare policy, population genetics and evolutionary dynamics of small populations, conservation biology, evolutionary algorithms, genetic search, problem solving using biologically inspired genetic algorithms, and interdisciplinary approaches to biology.

b) The researcher Co-I and PDRA employed on the project.

c) Members of the wider public with interests in antibiotics, healthcare, medicine, evolution and conservation.

d) All those involved in dealing with the current crises in antibiotic resistance (ultimately all who will benefit from the use of antibiotics which are currently becoming unusable due to the evolution of antibiotic resistant microbes).

e) Charities and organisations with an interest in developing conservation strategies and understanding the threats to populations at risk of extinction.

How will they benefit?

a) The wider scientific community will benefit as outlined in the Academic Beneficiaries section.

b) The researcher Co-I and PDRA will benefit from training, both in the general practicalities of cross-disciplinary research and, in the case of the researcher-Co-I, specific training in a next-generation sequence analysis (see Pathways to Impact).

c) As we have discovered through our existing work on antibiotic resistance, the wider public have strong interests in issues surrounding antibiotic resistant microbes and their evolution. This research will shed new light on this issue in terms of the role of mutation, population size and the effects of different fitness landscapes. They will benefit by gaining a deepening of understanding of the fundamental science behind the current crisis. Beyond that, this relevance offers a route in to inspiring interest in a range of STEM subjects and the interaction between them, providing a real world case study emphasising their importance to society

d) In the long-term this research could impact healthcare strategy through drug regime policy. Specifically, the use of combinations of antibiotics is becoming increasingly important and, depending on the results of this project, it may become clear that mutation rates and available evolutionary trajectories, in combination with population size, will result in predictably different outcomes if antibiotics are applied in different regimes.

e) Here we investigate fundamental theoretical issues of small population size and whether they are truly relevant to biological systems. While we use antibiotic resistant microbes as a tractable system, if we discover biological relevance, this will be applicable to animals as much as microbes. Therefore all those concerned with organisms at small population sizes, e.g. conservation organisations, could ultimately benefit from this work in uncovering the effect of mutation that could be cryptically causing endangered organisms to lose fit alleles, thereby influencing both conservation practice and policy.